Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C20H27N5O2
CAS Number:
Molecular Weight:
369.46
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
cilostazol
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1
InChI
1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChI key
RRGUKTPIGVIEKM-UHFFFAOYSA-N
Gene Information
human ... PDE3A(5139)
Looking for similar products? Visit Product Comparison Guide
General description
Cilostazol is a potent cyclic nucleotide phosphodiesterase inhibitor. It is mainly used as antiplatelet agent.
Application
Cilostazol USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Cilostazol Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Repr. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jae-Sik Jang et al.
Cardiology, 122(3), 133-143 (2012-07-27)
To evaluate the impact of cilostazol on the angiographic and clinical outcomes in patients undergoing percutaneous coronary intervention (PCI) with stents and treated with aspirin and thienopyridine. A total of 11 randomized controlled trials including 8,525 patients comparing triple antiplatelet
Deng-Feng Geng et al.
Cardiology, 122(3), 148-157 (2012-07-27)
Uncertainties still remain in terms of what kinds of patients benefit most from cilostazol-based triple antiplatelet therapy (TAT) after coronary stenting. We performed a meta-analysis of all relevant randomized controlled trials (RCTs) to investigate the effect of TAT versus dual
S Takahashi et al.
Journal of cardiovascular pharmacology, 20(6), 900-906 (1992-12-01)
Cilostazol, a cyclic AMP phosphodiesterase inhibitor, has been used as an antiplatelet agent. In the present study, we investigated the in vitro effect of cilostazol on DNA synthesis in rat aortic arterial smooth muscle cells (SMCs) in culture stimulated with
Kelly C Rogers et al.
The Annals of pharmacotherapy, 46(6), 839-850 (2012-06-07)
To evaluate the addition of cilostazol to standard dual antiplatelet therapy (DAT) with aspirin and clopidogrel in patients receiving coronary stenting. Relevant information was identified through a search of MEDLINE (1966-November 2011), International Pharmaceutical Abstracts (1960-2011), and Cochrane Databases (publications
James J Dinicolantonio et al.
The American journal of cardiology, 112(8), 1230-1234 (2013-07-06)
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has shown promise for the secondary prevention of stroke. A systematic review and meta-analysis of randomized controlled trials using Ovid
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service